Tag: Currax Pharmaceuticals

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Coronary/Structural Heart by Comments are Disabled

BRENTWOOD, Tenn., Aug. 27, 2024 /PRNewswire/ — Currax Pharmaceuticals LLC (“Currax”) today announced the results of a Cardiovascular Health Outcomes Analysis (HOA). The results showed there is no evidence of excess cardiovascular risk and no statistically significant difference in major…

Continue Reading →

Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC

Coronary/Structural Heart by 0 comments

– Performance-Based Agreement Provides for Currax’s 72 Sales Representatives to Detail Esperion’s Products – – Reinforces Esperion’s Focus on Driving Persistent Growth By More Than Doubling Sales Team – ANN ARBOR, Mich., April 19, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced an agreement with Currax Pharmaceuticals LLC that provides for all of […]

Continue Reading →